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a  b  s  t  r  a  c  t
Plasmodium  vivax  continues  to  cause  signiﬁcant  morbidity  outside  Africa  with  more  than  50%  of  malaria
cases  in many  parts  of  South  and South-east  Asia,  Paciﬁc  islands,  Central  and  South  America  being
attributed  to  P.  vivax  infections.  The  unique  biology  of  P. vivax,  including  its ability  to  form  latent  hypno-
zoites  that emerge  months  to years  later  to cause  blood  stage  infections,  early  appearance  of  gametocytesalaria vaccines
arasitic diseases
mmunity to malaria
lood stage malaria vaccines
re-erythrocytic stage malaria vaccines
before  clinical  symptoms  are  apparent  and  a shorter  development  cycle  in  the  vector  makes  elimination
of  P. vivax  using  standard  control  tools  difﬁcult.  The  availability  of  an  effective  vaccine  that  provides
protection  and  prevents  transmission  would  be  a valuable  tool  in  efforts  to  eliminate  P. vivax.  Here,  we
review  the  latest  developments  related  to  P. vivax  malaria  vaccines  and  discuss  the  challenges  as  well  as
directions  toward  the  goal  of developing  highly  efﬁcacious  vaccines  against  P. vivax  malaria.
© 2015  Published  by Elsevier  Ltd.  This  is  an  open  access  article  under  the CC BY  licenseransmission blocking malaria vaccines
. Introduction – why  a vaccine for Plasmodium vivax is
eeded
The last 10 years have seen a dramatic reduction in the burden
f malaria, with many countries in the Asia-Paciﬁc and the Amer-
cas seeing reduction of >90% in the number of clinical cases [1].
s a consequence, 34 countries are actively attempting to elimi-
ate malaria and the leaders of Central American and East Asian
ountries have declared their intention to eliminate malaria from
heir regions by 2020 and 2030, respectively [2,3]. In parallel to
his reduction in overall incidence, a pronounced shift in species
omposition has been observed with P. vivax now the predominant
lasmodium spp. in vast majority of countries outside Africa [1].
While the reasons for the shift in species composition are
ot entirely clear, the main reasons are likely to be related to
he following aspects of P. vivax biology: (i) its ability to relapse
rom long-lasting, dormant liver stages (the hypnozoites) [4] and
ii) its high transmission potential due to early and continuous
roduction of gametocytes, high infectivity to mosquitoes and
horter development cycle in the vector host compared to other
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Plasmodium spp. [5]. Relapses from emerging hypnozoites may  con-
tribute up to 80% of all P. vivax blood stage infections [6, Mueller
et al., unpublished data] and if not treated appropriately can cause
new blood-stage infections months to a few years after the primary
infection [7]. As there are no diagnostic tests that can diagnose dor-
mant liver-stage infections, undetectable hypnozoite carriers are
an important potential source of re-introduction of P. vivax. Unfor-
tunately, the only currently available drug to clear hypnozoites is
primaquine, which can cause severe hemolysis in people with glu-
cose 6-phosphate dehydrogenase (G6PD) deﬁciency [8]. The only
other anti-hypnozoite drug in clinical development, Tafenoquine,
carries the same risks of hemolysis as primaquine. [9] Given the lack
of a cheap, reliable point-of-care G6PD test, many P. vivax patients
do not currently receive adequate anti-hypnozoite treatment.
At all levels of transmission, asymptomatic and sub-microscopic
P. vivax infections are very common [10]. Most if not all of these
infections produce gametocytes [11] and likely contribute substan-
tially to maintaining P. vivax transmission [12]. These infections will
not be efﬁciently cleared unless speciﬁcally targeted with active
case detection and/or mass drug administration, which is logisti-
cally challenging and would again require treating large numbers
of individuals with asymptomatic infections or even those without
blood stage infections with primaquine to clear hypnozoites.
Despite the high frequency of asymptomatic carriers, numer-
ous clinical studies in diverse geographical locations have now
convincingly demonstrated that infection with P. vivax can lead
to severe disease and death [13–17]. P. vivax infections are, thus,
not benign as considered previously and new strategies to prevent
Y license (http://creativecommons.org/licenses/by/4.0/).
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. vivax malaria are urgently needed. These are particularly impor-
ant, where weak health systems and/or drug resistance make
fﬁcient cases management difﬁcult.
An additional challenge to the elimination of P. vivax lies in the
iology of its key vectors [18,19], many of which are outdoor bit-
ng and less anthropophillic than the main African P. falciparum
ectors [20]. As a result, traditional vector control measures such
s indoor residual spraying and insecticide-treated nets are less
ffective against P. vivax control in non-African settings. The faster
evelopment of P. vivax in the mosquito further impairs the effec-
iveness of vector control as a larger reduction in mosquito life-span
eeds to be achieved for a comparable impact on P. vivax transmis-
ion.
Vaccines against P. vivax with high efﬁcacy could help address
everal gaps in our current tool kit and greatly facilitate elim-
nation of P. vivax. A pre-erythrocytic vaccine that prevents
nfections would not only reduce the number of primary infec-
ions but by preventing the establishment of hypnozoites, also
educe the risk of multiple relapses contributing to continued
ransmission. Given that a single mosquito bite may  lead to 1
rimary infection and up to 4 relapses (Mueller et al., unpub-
ished data) it is likely that a pre-erythrocytic vaccine would have
 larger effect on P. vivax transmission compared to P. falcip-
rum transmission. Similarly, a blood-stage vaccine that blocks
arasite growth would not only prevent disease and death but
ay  also dramatically shorten the duration and lower the den-
ity of blood-stage parasitemia and associated gametocytemia, thus
reatly reducing the transmission potential of P. vivax-infected
ndividuals. Lastly, a transmission blocking vaccine would directly
lock infection of mosquito vectors and thereby not only accel-
rate the interruption of transmission but also safeguard against
e-emergence of transmission in areas where elimination has been
chieved.
. Feasibility of developing a vaccine for P. vivax vaccine
The epidemiology of P. vivax provides strong indication that
he development of P. vivax vaccines should be feasible. Under
atural exposure, clinical immunity to P. vivax is acquired signif-
cantly more rapidly both in high transmission settings such as
apua New Guinea, where the incidence of P. vivax malaria starts
eclining in the 2nd year of life [21] and clinical disease is virtu-
lly absent in children >5 years while P. falciparum disease remains
ommon in primary school children [22], as well as in lower trans-
ission settings such as Thailand [23], Sri Lanka [24] and Vanuatu
25]. Similarly, in malaria therapy trials effective clinical immu-
ity, even against heterologous challenge, was often observed after
s few as 1–5 P. vivax infections [26,27]. Semi-immune individ-
als generally exhibit very good control of blood-stage parasitemia
esulting in signiﬁcant numbers of sub-microscopic infections even
n low transmission settings [10] indicating development of effec-
ive blood stage immunity.
There is less evidence for naturally acquired immunity to pre-
rythrocytic stages. In limited trials with irradiated sporozoites,
rotection was achieved but only in subjects who  received very
igh numbers of sporozoites [28]. There is however good evidence
or naturally acquired transmission-blocking immunity. Early stud-
es in Sri Lanka showed that sera from P. vivax infected patients
ere very effective at suppressing infection of the parasites in
osquitoes and that the effect was dependent on antibodiesgainst P. vivax gametocytes and gametes [29]. Similar transmis-
ion blocking effects were later conﬁrmed in studies in Thailand
nd Colombia [30,31]. Together, these observations provide strong
vidence that the development of effective P. vivax vaccines should
e possible. (2015) 7489–7495
3. Target Product Proﬁle (TPP) for a P. vivax vaccine
Table 1 provides a Target Product Proﬁle (TPP) for a possible
vaccine for P. vivax malaria. The TPP describes the basic parame-
ters, both ideal as well as minimally acceptable, which the vaccine
should have. Industry uses such TPPs to guide product devel-
opment. A vaccine for P. vivax will likely be needed in settings
where transmission rates are low and the entire population is non-
immune. As a result, the vaccine will need to target the entire
population not just infants or children. Ideally a P. vivax vaccine
would both prevent P. vivax malaria with high efﬁcacy (>90%) and
also block P. vivax transmission. However, a minimally acceptable
target would be a vaccine that protects against P. vivax malaria
with high efﬁcacy (at least 80%). The TPP also describes other ideal
and minimally acceptable targets for parameters such as product
presentation, dosage schedule, co-administration and storage con-
ditions that are relevant for the design and development of a viable
vaccine. It would be useful to keep the TPP in mind as one reviews
current efforts toward development of vaccines for P. vivax malaria.
4. Leading P. vivax vaccine candidates
Efforts to develop vaccines against different stages of P. vivax
have been underway over past two decades. Here, we  will review
recent progress on leading pre-erythrocytic, blood stage and trans-
mission blocking P. vivax vaccine candidates. Table 2 summarizes
key information about the various vaccine candidates discussed in
this review. Due to restrictions of space, this review is limited to P.
vivax vaccine candidates that have reported progress toward clin-
ical development and does not cover all the P. vivax antigens that
are at an early research stage of vaccine development. A more com-
prehensive survey of malaria vaccine candidates (both P. falciparum
and P. vivax) can be found in the ‘Rainbow Tables’ of global malaria
vaccine projects [32].
4.1. Pre-erythrocytic stage P. vivax vaccine candidates
4.1.1. P. vivax circumsporozoite protein (PvCSP)
Of the P. falciparum vaccine RTS,S, which is based on the
P. falciparum circumsporozoite protein (PfCSP) has consistently
demonstrated protection in the range of 30–50% against P. falcipa-
rum malaria in Phase II and Phase III trials conducted in children
and infants [33,34]. These studies clearly demonstrate that it is
possible to elicit partial protection against P. falciparum malaria by
immunization with constructs based on CSP. These observations
support the development of a vaccine for P. vivax malaria based on
the homologous P. vivax CSP (PvCSP).
Yadava et al. have constructed a recombinant PvCSP chimeric
antigen (VMP001) that contains the repeat (R) sequences of the two
major PvCSP alleles, VK210 (9 repeats) and VK247 (1 repeat) fused
to N- and C-terminal conserved regions of PvCSP from the VK210
allele [35]. VMP001 formulated with AS01B was  tested in a Phase
I/IIa study in malaria naïve healthy volunteers [36]. It was  found
to be safe and induced high titer antibody responses. Although the
vaccine showed an increase in pre-patent period in some immu-
nized volunteers, it did not induce sterile protection against P. vivax
sporozoite challenge in any of the volunteers [36].
The immunogenicity of E. coli produced VMP001 was com-
pared with CSV-S,S, a RTS,S-like vaccine candidate that contains
a mixture of free hepatitis B surface antigen (HBsAg) and S. cere-
visiae produced fusion protein containing VMP001 sequences fused
to HBsAg. CSV-S,S induced higher levels of PvCSP-speciﬁc anti-
bodies than soluble VMP001 when both were formulated with
the adjuvant AS01 [37]. Efﬁcacy of VMP001 formulated with CpG
10104 + Montanide ISA720 has also been tested by challenging
I. Mueller et al. / Vaccine 33 (2015) 7489–7495 7491
Table  1
Target Product Proﬁle for P. vivax vaccine.
Item Desired target Minimally acceptable target
Indication Prevention of P. vivax malaria and interruption of P. vivax
transmission
Prevention of P. vivax malaria
Target  Population All age groups, pregnant women, immuno-deﬁcient
persons
Healthy persons including infants, children and adults
Route  of Administration Oral or IM or SC IM or ID or SC
Product Presentation Single dose, auto-disposable, pre-ﬁlled device Lyo/liquid formulation. Vials may  be accompanied with
separate vial containing adjuvant. May  require
reconstitution
Dosage Schedule Single dose, no booster required 2 doses, booster may  be required 4–6 months after 2nd
dose
Efﬁcacy  Greater than 90% efﬁcacy against P. vivax malaria and
reduces Reffective < 1 for all P. vivax strains for at least 2 years
Greater than 80% efﬁcacy against P. vivax malaria for at
least 1 year
Co-administration Non-inferiority of responses to EPI vaccines when
co-administered with other vaccines
Stand-alone product not co-administered with other
vaccines
Shelf-life 36 months 24 months
Storage Ambient temperature and withstand freeze–thaw 2–8 ◦C
Product registration WHO  prequaliﬁed, registered with FDA, EMEA WHO  prequaliﬁed or competent national regulatory
agency
IM,  intramuscular; SC, subcutaneous; ID, intradermal; Reffective, effective reproduction rate upon introduction of vaccine; EPI, expanded program of immunization; WHO,
World Health Organization; FDA, Federal Drug Administration; EMEA, European Medicines Agency.
Table 2
P. vivax vaccine candidates under development.
Vaccine candidate Development Phase Life cycle stage Antigen Delivery system Ref.
VMP001 Phase I/IIa Liver stage PvCSP Rec. protein-AS01B [35,36]
CSV-S,S Pre-clinical Liver stage PvCSP HBsAg fusion-AS01B [37,38]
PvCSP-LSP Phase I Liver stage PvCSP Synthetic peptides- Montanide ISA 720 [41–43]
ChAd63-PvTRAP/MVA-PvTRAP Phase I Liver stage PvTRAP Prime-boost, viral vectors [44]
PvDBPII Pre-clinical Blood stage PvDBP Rec. protein-GLA-SE [56,57]
PvDBPII-DEKnull Pre-clinical Blood stage PvDBP Rec. protein [59]
ChAd63-PvDBPII/MVA-PvDBPII Pre-clinical Blood stage PvDBP Prime boost, viral vectors [60]
PvMSP119 Pre-clinical Blood stage PvMSP1 Rec. protein-Montanide ISA720 [63,64]
ChAd63-PvAMA1/MVA-PvAMA1 Pre-clinical Blood stage PvAMA1 Prime-boost, viral vectors [68]
PvAMA1 Pre-clinical Blood stage PvAMA1 Rec. protein-adjuvant [69]
Pvs25H Phase 1 Trans. stage Pvs25 Rec. protein-alhydrogel; Rec. protein-Montanide ISA 51 [72,73]
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otus nancymaae monkeys with P.vivax sporozoites. Sixty six per-
ent of vaccinated monkeys were completely protected following
hallenge with P. vivax sporozoites. Antibodies against the repeat
egion of PvCSP showed a statistical association with protection
38].
VMP001 has also been formulated in nanoparticles formed as
nterbilayer crosslinked multilamellar lipid vesicles (ICMVs) com-
osed of polylactide-co-glycolide acid (PLGA) and a lipid membrane
39,40]. Immunization with the resultant VMP001-ICMVs formu-
ated with monophosphoryl lipid A (MPLA) induced potent humoral
esponses that lasted for over 1 year in mice at 10-fold lower doses
hen compared with formulations of soluble VMP001 [39]. Addi-
ionally, VMP001-ICMVs enhanced germinal center formation at
ow doses of antigen where no GC induction occurred with soluble
rotein [39]. Antibodies raised by VMP001-NP vaccinations also
xhibited enhanced avidity and afﬁnity against the PvCSP repeat
omains [39].
Based on the identiﬁcation of B and T cell epitopes in PvCSP,
ong synthetic peptides (LSPs), N (N-terminal), R (Repeat), and C
carboxyl terminal) have also been developed for assessment as
accine candidates [41]. The three LSPs have been tested in Phase I
linical trials both individually, formulated with Montanide ISA720
n escalating doses (10 g, 30 g and 100 g/dose) [42], and as
 mixture of 3 LSPs (50 and 100 g/dose of mixture of peptides)
ormulated with Montanide ISA 720 and Montanide ISA 51 [43].
ntibodies were elicited against each of the peptides in the mixture
nd recognized native PfCSP on the surface of sporozoites [43]. The
ontanide ISA51 formulation elicited higher antibody titers and
nferferon production.28 Rec. protein-adjuvant [70]
APN1 Rec. protein-adjuvant [74]
4.1.2. P. vivax thrombospondin related adhesive protein (PvTRAP)
Bauza et al., have used the chimpanzee adenovirus ChAd63
and modiﬁed vaccinia virus Ankara (MVA) to express P. vivax
thromospondin-related adhesive protein (PvTRAP) [44]. Priming
with recombinant ChAd63 expressing PvTRAP followed by boosting
with recombinant MVA  expressing PvTRAP induced high anti-
body titers and T cell responses in mice [44]. With the help of
an infection model using transgenic P. berghei parasite expressing
P. vivax TRAP, the authors found that both CD8+ T cells and anti-
bodies mediate protection, suggesting that recombinant ChAd63
and MVA  expressing PvTRAP have potential for development as
pre-erythrocytic-stage vaccine candidates [44].
4.2. Blood stage P. vivax vaccine candidates
4.2.1. Receptor-binding region II of P. vivax Duffy binding protein
(PvDBPII)
PvDBP is a microneme protein that binds the Duffy blood
group antigen on human reticulocytes to mediate invasion by P.
vivax merozoites [45]. A conserved, 330 amino acid cysteine-rich
region, referred to as region II (PvDBPII), within the 130 kDa  PvDBP
mediates engagement with Duffy antigen [46]. Blocking this crit-
ical receptor–ligand interaction with antibodies elicited against
PvDBPII offers a potential mechanism to block invasion [47] and
prevent P. vivax malaria. Recently, it has been reported that P. vivax
can also infect Duffy-negative individuals suggesting that the par-
asite has alternate invasion pathways that do not depend on Duffy
antigen [48]. However, P. vivax ligands and erythrocyte receptors
involved in invasion of Duffy-negative reticulocytes remain to be
7 cine 33
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dentiﬁed. Also, it remains to be seen how commonly such alter-
ative pathways are used for reticulocyte invasion by P. vivax ﬁeld
solates from different geographical locations. It may  be necessary
o target these interactions in addition to PvDBPII if such invasion
athways are commonly used.
The amino acid residues within PvDBPII that make contact
ith the Duffy antigen include conserved hydrophobic and pos-
tively charged residues in the central region between cysteines
 and 7 of PvDBPII that form a relatively ﬂat, surface exposed
inding site [49–51]. A glycan masking study demonstrated that
-glycosylation at a site adjacent to the predicted Duffy inter-
ction site abolished PvDBPII binding to Duffy and resulted in
eaker binding inhibitory antibody responses when the glyco-
ylated PvDBPII was used for immunization [52]. In contrast,
ddition of N-glycosylation sites distal to the predicted Duffy-
inding site did not inhibit binding, and elicited better binding
nhibitory antibodies when compared to wild-type PvDBPII [52].
hese studies validated the mapping of critical binding residues
o the central region of PvDBPII. A ‘receptor-mediated dimeriza-
ion model’ that predicts additional binding residues in the dimer
nterface has also been proposed [53]. In this model, interaction
ith the Duffy antigen leads to dimerization of PvDBP, which may
e functionally important [53]. Importantly, studies on sequence
olymorphisms in PvDBP have demonstrated that the binding
esidues identiﬁed in PvDBPII, whether in the dimer interface [53]
r on the surface [51], are highly conserved in P. vivax ﬁeld iso-
ates from diverse geographical regions [54]. Given that the Duffy
ecognition site appears to be conserved, inhibitory antibodies
aised against PvDBPII should be effective against diverse P. vivax
trains.
A treatment re-infection study conducted in children in
 malaria endemic region of Papua New Guinea has shown
hat naturally acquired high titer anti-PvDBPII binding-inhibitory
ntibodies are associated with protection against P. vivax
nfection [55]. Further, as predicted by structure-function studies
f the PvDBPII-Duffy antigen interaction, the inhibitory activity of
nti-PvDBPII binding inhibitory antibodies is strain-transcending
55]. However, natural acquisition of such high blocking antibodies
ollowing exposure to P. vivax infection is rare [55].
Immunogenicity of E. coli-produced recombinant PvDBPII has
een extensively evaluated. In rhesus monkeys PvDBPII formulated
ith human-compatible adjuvants Alhydrogel, Montanide ISA720
nd AS02A elicits high titer binding inhibitory antibodies [56].
mmune responses have also been tested in mice with GLA-SE, R848
nd their combinations [57]. Formulation with GLA-SE increases
he diversity of IgG variable region sequences, and elicits strain-
ranscending antibodies that efﬁciently inhibit PvDBPII variants
rom diverse strains [57]. These observations support development
f a vaccine based on PvDBPII.
Recently, Chootong et al., have reported that dominant, sur-
ace exposed B cell epitopes on PvDBPII that are polymorphic
ay  drive antibody responses against polymorphic residues while
imiting induction of antibodies against critical conserved epi-
opes [58]. Recombinant DBPII that lacks one such strain-speciﬁc
mmune-dominant variant epitope ‘DEK’ that is normally present
n PvDBPII, leaving intact the less immunogenic but conserved
eutralizing epitopes, has been constructed [59]. The resultant
BPII-DEKnull protein bound to erythrocytes and elicited func-
ional anti-DBPII antibodies. While the binding inhibitory response
licited by recombinant DBPII-DEKnull was lower than the PvDBPII
al I, the functional activity of antibodies had a broader cover-
ge of diverse DBPII alleles [59]. Immunization with recombinant
hAd63 and MVA  expressing PvDBPII in prime-boost regimens also
ields high titer binding inhibitory antibodies [60]. Priming with
hAd63 expressing PvDBPII followed by boosting with recombi-
ant PvDBPII formulated with adjuvants such as Montanide ISA720 (2015) 7489–7495
or Abisco yields higher ELISA and binding inhibitory titers com-
pared to ChAd63-MVA prime-boost regimens [60].
4.2.2. P. vivax merozoite surface proteins
Merozoite Surface Protein 1 (MSP1) is abundantly expressed on
the merozoite surface and is associated with acquisition of natu-
rally acquired humoral and cellular immune responses. Proteolytic
processing of ∼195 kDa precursor protein yields smaller fragments
(83, 30, 38 and 42 kDa) during invasion. The 42 kDa fragment is fur-
ther cleaved into 33 kDa and 19 kDa C terminal fragments. MSP119
contains domains that share homology with epidermal growth fac-
tor (EGF). The 19 kDa cysteine-rich fragment remains attached to
the surface of released merozites [61] in the form of a protein
complex. Studies in Macaca sinica monkeys with recombinant P.
cynomolgi MSP142 and MSP119 showed that both fragments were
highly immunogenic and protected against P. cynomolgi blood-
stage challenge [62]. These studies provide an example for the use
of P. cynomolgi as a model for P. vivax vaccine development. This
non-human primate model could be used more widely to evaluate
the potential of P. vivax vaccine candidates although ﬁnal proof of
concept will have to come from clinical trials against artiﬁcial or
natural challenge.
Recombinant PvMSP119 fused with two  T-helper epitopes from
the 33 kDa PvMSP1 fragment (PvMSP133) was  tested for immuno-
genicity in Callithrix jacchus monkeys [63]. Recombinant PvMSP119
has also been tested in combination with PvDBPII in mice. Immu-
nization with combination of PvDBPII and PvMSP119 formulated
with the Montanide ISA 720 elicited high titer antibody responses
against both antigens [64].
Other merozoite surface proteins that have been explored as
potential antigens for vaccine development include PvMSP3 and
PvMSP9. In a study of children aged 1–3 years residing in a malaria
endemic region of Papua New Guinea, Stanisic et al. [65] have
shown that naturally acquired antibodies against the C-terminal
Block II of PvMSP3 and the N-terminal domain of PvMSP9 are
signiﬁcantly associated with protection from symptomatic P. vivax
malaria and prospective risk during 16 months of active follow-up.
The region that contains Block II of PvMSP3 and the N-terminal
region of PvMSP9, are highly conserved across P. vivax isolates
[64]. In another study, high titer antibodies to interspecies con-
served blocks 2–5 of PvMSP1 (PvMSP1 ICB2-5) were also found to
be associated with clinical protection against P. vivax suggesting
that other regions of PvMSP1 could also be considered for vaccine
development [66].
4.2.3. P. vivax apical merozoite antigen 1 (PvAMA1)
PvAMA1, a microneme-secreted 66 kDa protein contains 3
domains referred to as DI, DII, and DIII with intra-domain disul-
phide linkages [67]. Recently, Bouillet et al. [68] have studied
immunogenicty of PvAMA1 using adenovirus and recombinant
protein in different prime boost regimens. The ‘Protein/Ad’
group (protein formulated with Montanide ISA720 followed
by Ad5PvAMA1) elicited long-lasting PvAMA1-speciﬁc antibody
responses, as well as memory T cell responses [68]. PvAMA-1 has
also been expressed as a secreted protein in Pichia pastoris [69]. For-
mulations with saponin Quil A and incomplete Freund’s adjuvant
elicited higher antibody titers when compared to monophoshoryl
lipid A (MPLA) or Alum plus MPLA. Importantly, PvAMA-1 elicited
invasion inhibitory antibodies against diverse P. vivax strains [69].
4.3. Transmission blocking P. vivax vaccine candidates4.3.1. Pvs25 and Pvs28
Parasite proteins expressed on surface of zygote (Pvs25)
and ookinete (Pvs28) stages each contain four cysteine-
rich epidermal growth factor-like domains with a C-terminal
cine 33
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lycosylphosphatidylinositol (GPI) anchor. Recombinant Pvs25
nd Pvs28 expressed in Saccharomyces cerevisiae formulated with
lhydrogel elicits potent antibodies in mice that completely inhibit
arasite development in mosquitoes in membrane feeding assays
70]. Recombinant Pvs25 formulated with Montanide ISA720 and
lhydrogel were tested for immunogenicity in rhesus [71]. The
ontanide ISA 720 group elicited antibodies with 10-fold higher
ecognition titers with potent transmission blocking activity
ompared to Alhydrogel group [71].
Pvs25H, a vaccine formulation of Pvs25 with Alhydrogel was
ested in a dose-escalation (5, 20, 80 g/dose) Phase I trial in
ealthy volunteers [72]. The formulations were found to be safe and
nduced high titer antibodies in a dose dependent manner. How-
ver, only a 20–30% reduction in the number of infected mosquitoes
as observed with sera from immunized individuals in membrane
eeding assays. Though the vaccine provided proof of principle for
evelopment of a transmission blocking vaccine based on Pvs25,
igher levels of transmission blocking activity are needed for an
ffective deployable vaccine. In a separate trial, Pvs25 formulated
ith Montanide ISA 51 generated transmission blocking activity,
ut the formulation was found to be highly reactogenic and the
tudy was terminated [73].
.3.2. AnAPN1
Alanyl aminopeptidase 1 (AnAPN1) is a highly conserved midgut
urface antigen of Anopheles mosquitoes that is essential for
okinete invasion and development. Rabbit antibodies against
nAPN1 have shown transmission blocking activity against both
. vivax and P. falciparum across divergent anopheline species
upporting the development of an AnAPN1-based transmission
locking vaccine [74].
. Challenges and directions for P. vivax vaccine
evelopment
The unique characteristics of P. vivax pose some speciﬁc chal-
enges in studying its biology and designing strategies to control
t. For example, the lack of a method for continuous culture of P.
ivax blood stages makes it difﬁcult to perform growth inhibition
ssays to identify synergistic combinations of blood stage antigens
hat can be targeted to inhibit P. vivax blood stage growth high
fﬁciency. Several groups have recently succeeded in establishing
hort-term P. vivax culture for invasion assays using enriched retic-
locytes from cord blood [75]. Such methods for short term P. vivax
ulture are still dependent on access to fresh P. vivax isolates from
alaria patients limiting the routine use of such assays to endemic
egions. Noulin et al. [76] have shown that immature reticulocytes
erived from CD34+ hematopoietic stem/progenitor cells (HSPC)
ollected from umbilical cord blood were invaded efﬁciently by P.
ivax. In addition, CD34+-enriched cells could be further expanded
n vitro to generate more reticulocytes. Such approaches could be
sed to identify antigen combinations that may  be targeted to yield
ynergy and high rates of inhibition of invasion. They may  also lead
o development of methods for long-term culture of P. vivax blood
tages.
In the absence of a P. vivax blood-stage culture system, produc-
ion of infected mosquitoes for sporozoite or transmission stage
tudies also requires access to P. vivax patients in endemic areas. In
rder to study hepatocyte invasion stages of P. falciparum as well as
. vivax, attempts have been made to establish in vitro liver mod-
ls [77,78]. In addition, a reliable humanised mouse model for P.
ivax liver stages is now available [79]. Both approaches will help
o identify and test novel drugs and vaccines targeting hepatocyte
tages. Studies on expression of parasite proteins in hypnozoites (2015) 7489–7495 7493
will determine if these latent stages can also be targeted with novel
drugs and vaccines.
The development of a safe and reproducible P. vivax sporozoite
challenge model in malaria-naïve humans can greatly accelerate
clinical development of P. vivax vaccines. Herrera et al. have demon-
strated the robustness and reproducibility of the P. vivax sporozoite
challenge model [80,81], which should allow evaluation of efﬁcacy
of both pre-erythrocytic and blood stage P. vivax vaccines. A P. vivax
blood stage challenge model that establishes experimental blood
stage infection in human subjects by transfer of cryopreserved P.
vivax patient isolates [82] could also be used to evaluate efﬁcacy
of blood stage P. vivax vaccines. The use of sporozoite and blood
stage challenge models can greatly help validate and down select
P. vivax vaccine candidates for further clinical testing in more time
consuming and expensive ﬁeld trials against natural challenge in
endemic areas.
6. Conclusion
Given that a P. vivax vaccine will, in most cases, be used in low
transmission settings, ideally one would want a vaccine that has
high efﬁcacy (more than 90%) and blocks transmission (Table 1).
The development of such a vaccine will likely require combination
of multiple antigens that provide synergy to achieve high efﬁcacy.
For example, achieving high rates of blood stage growth inhibition
may  require targeting a combination of key blood stage antigens
involved in reticulocyte invasion. In addition, combination of blood
stage antigens with liver stage antigens may  be needed to achieve
high efﬁcacy and inclusion of antigens from sexual and mosquito
stages will be needed to inhibit of transmission. As seen above,
most of the vaccines that are currently under development target
individual stages and are based on single antigens. It is necessary to
initiate efforts to combine antigens both within and across develop-
mental stages to achieve synergy and attain the goal of developing
a vaccine for P. vivax malaria with high efﬁcacy.
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